Highlights Kane Biotech Inc.

Equities

KNE

CA4838092084

Market Closed - Toronto S.E. Other stock markets 03:47:57 2024-05-31 pm EDT			5-day change	1st Jan Change
0.125 ^CAD	-3.85%		-3.85%	+56.25%

May. 23	Kane Biotech Q1 Loss Widens Despite Revenue Gains; to Report a Q2 Gain Following Sale of STEM Animal Health	MT
May. 23	Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kane Biotech Q1 Loss Widens Despite Revenue Gains; to Report a Q2 Gain Following Sale of STEM Animal Health	May. 23	MT
Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23	CI
Kane Biotech Expands Wound Care Portfolio with Patented Schultz Biofilm Wound Map	May. 15	MT
Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	Apr. 15	MT
Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	Apr. 14	CI
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	Apr. 11	MT
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997	Mar. 26	MT
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	Mar. 20	MT
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	Jan. 31	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc..	Dec. 19	CI
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue	Nov. 28	MT
Kane Biotech Brief: Loss for Q3 of 2023 was ($1,197,889), an increase of 41% compared to ($851,597) for the quarter ended September 30, 2022	Nov. 28	MT
Kane Biotech Brief: Total revenue for three months ended September 30, 2023 was $717,852, an increase of 26% compared to $571,686 in three months ended September 30, 2022	Nov. 28	MT
Kane Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Kane Biotech Inc. and ProgenaCare Global Launch Newly Rebranded Revyve Antimicrobial Wound Care Fall Forum	Nov. 02	CI
Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum	23-10-25	MT
Kane Biotech Inc. to Exhibit At Symposium on Advanced Wound Care Fall Forum	23-10-25	CI
Kane Biotech Second-Quarter Loss Widens Even as Revenue Rises 68%	23-08-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kane Biotech Inc.

Equities

KNE

CA4838092084

Highlights

Filters